In-vitro Diagnostics Market Trends Size Share Growth and Forecast Analysis 2034
In-vitro Diagnostics Market Trends Size Share Growth and Forecast Analysis 2034
The in-vitro diagnostics market growth in 2026 is being shaped by increasing demand for diagnostic solutions, technological advancements, rising disease prevalence, and the growing focus on personalized medicine. Market participants are investing in research and development activities to introduce technologically advanced products and novel diagnostic systems. The increasing adoption of advanced testing technologies and the expansion of applications across healthcare settings are expected to support market growth through the forecast period.
According to Fortune Business Insights, the global in-vitro diagnostics (IVD) market size was valued at USD 77.73 billion in 2025 and is expected to grow from USD 81.83 billion in 2026 to USD 135.65 billion by 2034, exhibiting a CAGR of 6.50% during the forecast period. North America dominated the in-vitro diagnostics market with a market share of 37.70% in 2025. In-vitro diagnostics are medical devices used to perform diagnostic tests on biological samples, including blood, urine, and tissue. These tests support the detection and monitoring of infectious diseases, autoimmune diseases, and several other medical conditions and can also help analyze changes in drug therapy.
Increasing Prevalence of Chronic Diseases: The growing prevalence of acute and chronic disorders, including cardiovascular, genetic, and neurological diseases, is increasing demand for IVD products. Early diagnosis enables healthcare professionals to identify conditions and select appropriate treatments. The expanding geriatric population, which is more susceptible to disorders such as liver disease, hypertension, cardiovascular conditions, and kidney diseases, is another factor supporting market growth.
Government Support and Funding: Government organizations, agencies, and associations are increasingly supporting awareness initiatives related to diagnostic testing. The World Health Organization released its 2023 Essential Diagnostics List, providing an evidence-based register of IVDs to support national diagnostic choices. Increasing research and development initiatives and product launches are also expected to contribute to market expansion.
High Instrument Costs: High costs associated with IVD instruments and their maintenance can restrict adoption, particularly in emerging countries. The requirement for skilled professionals to operate certain diagnostic products can further increase maintenance and operating costs. Fortune Business Insights notes that RT-PCR systems can range from USD 15,000 to more than USD 90,000, contributing to limited adoption in some emerging markets.
Rising Adoption of Molecular Diagnostics: Molecular diagnostics represents one of the most dynamic techniques within the IVD industry. These techniques have become widely used for transplant and transfusion diagnostics and disease testing. Their comparatively high sensitivity enables healthcare providers and laboratory professionals to identify infectious diseases from small sample quantities. Increasing use of molecular biomarkers in cancer diagnosis and advancements such as next-generation sequencing are expected to create opportunities for market participants.
Growing Penetration of Point-of-Care Testing: Point-of-care testing is gaining attention because of benefits including convenience, ease of testing, efficiency, lower costs, and rapid results. Increasing demand for rapid diagnostics is encouraging companies to develop technologically advanced point-of-care devices. Product launches and regulatory approvals are further supporting adoption across decentralized healthcare settings.
Technology and Personalized Medicine: The integration of automation, artificial intelligence, and machine learning into IVD devices is enhancing diagnostic accuracy and efficiency. At the same time, IVD solutions are increasingly being used to support personalized medicine by helping tailor treatments according to individual genetic profiles.
The global in-vitro diagnostics market is semi-consolidated, with prominent companies including F. Hoffmann-La Roche Ltd., Abbott, and Siemens Healthineers AG holding significant market positions. Companies are focusing on research and development, new product introductions, geographic expansion, partnerships, and other strategic initiatives to strengthen their market presence. F. Hoffmann-La Roche Ltd. has emphasized technologically advanced products and novel systems, while Abbott benefits from a diversified product portfolio and global presence.
F. Hoffmann-La Roche Ltd. (Switzerland)
Abbott (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Sysmex Corporation (Japan)
Siemens Healthineers AG (Germany)
BD (U.S.)
Seegene Inc. (Republic of Korea)
DiaSorin S.p.A. (Italy)
Quest Diagnostics Incorporated (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
By product type, the market is segmented into
By Product Type (Instruments and Reagents & Consumables)
By Technique (Immunodiagnostics [Enzyme Linked Immunosorbent Assay, Fluorescence immunoassay, Rapid test], Clinical Chemistry, Molecular Diagnostics, Hematology)
By Sample (Blood, Urine, Saliva, Tissue), By Setting (Laboratories, Point-of-Care)
By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Allergy)
By End-user (Clinical Laboratories, Hospitals, Physician’s Offices)
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-ivd-market-101443
North America: North America represented USD 29.33 billion in 2025, accounting for 37.70% of the global market, and is expected to reach USD 30.92 billion in 2026. The presence of major companies, favorable government regulations, established diagnostic infrastructure, and adoption of technologically advanced diagnostic techniques support regional growth.
Europe: Europe generated USD 20.46 billion in 2025, representing 26.30% of the global market, and is expected to reach USD 21.50 billion in 2026. Established healthcare infrastructure, healthcare expenditure, disease prevalence, and growing point-of-care device launches are supporting regional adoption.
Asia Pacific: Asia Pacific accounted for 23.00% of the global market in 2025, with a valuation of USD 17.86 billion, and is expected to reach USD 18.94 billion in 2026. Rising healthcare expenditure, disease prevalence, improving approval and reimbursement policies, and healthcare infrastructure expansion are expected to drive regional growth. China is expected to reach USD 6.61 billion, India USD 3.37 billion, and Japan USD 4.32 billion in 2026.
The in-vitro diagnostics market is expected to maintain a positive growth trajectory through 2034 as healthcare providers increasingly adopt advanced diagnostic technologies. Rising chronic and infectious disease prevalence, growing demand for early diagnosis, molecular diagnostic advancements, point-of-care testing, personalized medicine, automation, and artificial intelligence are expected to influence future market development. At the same time, regulatory complexities, high instrument costs, reimbursement limitations, competition, and supply chain issues remain important considerations for industry participants.
Explore Japan’s Market Opportunities - Latest -in-vitro diagnostics (IVD) market - Insights